quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:30:00·16d
PRRelease
Arcutis Biotherapeutics Inc. logo
Incyte Corp. logo
Palvella Therapeutics Inc. logo

Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

ARQT· Arcutis Biotherapeutics Inc.INCY· Incyte Corp.PVLA· Palvella Therapeutics Inc.
Health Care
Original source

Companies

  • ARQT
    Arcutis Biotherapeutics Inc.
    Health Care
  • INCY
    Incyte Corp.
    Health Care
  • PVLA
    Palvella Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 16INCYUpdateJefferies$94.00
  • Feb 5INCYUpdateH.C. Wainwright$135.00
  • Jan 20INCYUpdateWells Fargo$107.00
  • Jan 7PVLAUpdateMizuho$205.00
  • Dec 8INCYUpdateMizuho$121.00
  • Dec 5PVLAUpdateBTIG Research$167.00

Related

  • PR21h
    MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia
  • PR1d
    Arcutis' ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
  • SEC2d
    SEC Form S-8 filed by Arcutis Biotherapeutics Inc.
  • SEC2d
    SEC Form DEFA14A filed by Arcutis Biotherapeutics Inc.
  • SEC2d
    SEC Form DEF 14A filed by Arcutis Biotherapeutics Inc.
  • INSIDER2d
    SEC Form 4 filed by Cagnoni Pablo J
  • PR3d
    Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
  • INSIDER6d
    SEC Form 4 filed by Meury William
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022